Ono Pharmaceutical has been granted a patent for a method to enhance immunity against solid cancer. The method involves administering an Allergin-1 antagonist, specifically an Allergin-1-fusion protein, to a human patient with solid cancer. The antagonist inhibits Allergin-1 signaling and comprises the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3. This method aims to suppress the progress, recurrence, and/or treat cancer in patients with insufficient therapeutic efficacy from tumor immunotherapy or in combination with an anti-cancer drug. GlobalData’s report on Ono Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ono Pharmaceutical, peptide pharmacophores was a key innovation area identified from patents. Ono Pharmaceutical's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method for enhancing immunity against solid cancer using allergin-1 antagonist
A recently granted patent (Publication Number: US11638744B2) describes a method for enhancing immunity against solid cancer by administering an Allergin-1 antagonist to a human patient with solid cancer. The Allergin-1 antagonist is an Allergin-1-fusion protein that is soluble in an aqueous solution and consists of the whole extracellular domain of Allergin-1 and an immunoglobulin Fc region. This fusion protein is capable of inhibiting Allergin-1 signaling, which enhances immunity against the solid cancer. The Allergin-1 antagonist is administered in conjunction with a pharmaceutically acceptable carrier.
The patent claims specify the dosage range for administering the Allergin-1 antagonist, which can range from 0.1 µg/kg to 300 mg/kg per dose or from 0.1 mg/kg to 10 mg/kg per dose. The Allergin-1 antagonist is effective in suppressing the progress, recurrence, and treatment of various types of solid cancers, including malignant melanoma, lung cancer, head and neck cancer, breast cancer, ovarian cancer, bone and soft tissue sarcoma, and many others.
In some cases, the solid cancer patient may have already been treated or is being treated with another therapeutic agent that is an anti-cancer drug. The patent claims mention specific fusion proteins and antibodies that can be used as anti-cancer drugs, such as PD-L1 fusion protein, PD-L2 fusion protein, anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CTLA-4 antibody, and many others. The method can involve administering the Allergin-1 antagonist and the anti-cancer drug separately or in a single preparation.
The patent claims also mention specific anti-cancer drugs that can be administered in combination with the Allergin-1 antagonist, including Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, Ipilimumab, and Tremelimumab.
Overall, this patent describes a method for enhancing immunity against solid cancer by administering an Allergin-1 antagonist, which is an Allergin-1-fusion protein, to a human patient. The method can be used alone or in combination with other anti-cancer drugs to suppress the progress, recurrence, and treatment of various types of solid cancers.
To know more about GlobalData’s detailed insights on Ono Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
